Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0024623 (gastric cancer)
 36,219 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The chemosensitivities of 41 poorly differentiated gastric cancer tissues were compared with that of 16 well differentiated tissues, using the in vitro succinate dehydrogenase inhibition test. These human tissues obtained at the time of surgery were exposed to six different antitumor drugs: carboquone (CQ), adriamycin (ADM), mitomycin C (MMC), aclacinomycin A (ACR), cisplatin (DDP) and 5-fluorouracil (5-FU). The chemosensitivity was determined as positive when the succinate dehydrogenase (SD) activity of the drug exposed cells was decreased to below 50% of that of control cells, on day 3 of exposure. Decrease in SD activity was remarkable in the poorly differentiated tissues, compared to the well differentiated tissues, exposed to ADM, MMC, DDP and 5-FU. The sensitive rates were higher in the poorly differentiated tissues than in the well differentiated tissues, against all six antitumor drugs. Sixty-three per cent of the poorly differentiated tissues were sensitive to more than three antitumor drugs, in an identical tissue, but the rate was only 19% in the well differentiated tissues. The resistant rates to all drugs tested were 20% in the poorly differentiated and 31% in the well differentiated tissues. This would indicate that patients with a poorly differentiated gastric cancer will probably show a better response to antitumor drugs, compared to those with a well differentiated type.
 ...
PMID:Poorly differentiated human gastric carcinoma is more sensitive to antitumor drugs than is well differentiated carcinoma. 303 3

A 58-year-old woman who had undergone subtotal gastrectomy for advanced gastric cancer yielded massive ascites after 6 months. The cytology of ascites showing Class V indicated recurrence of peritoneal dissemination in the gastric cancer. Since laparotomy disclosed diffusely small tubercular seedings in all areas of the peritoneal cavity, she received continuous hyperthermic peritoneal perfusion (CHPP) with 300 mg Cisplatin and 30 mg Mitomycin C. After CHPP ascites disappeared for 4 months. Macroscopically and microscopically, there was no cancerous lesion in the peritoneal cavity by following second-look operation. This result encouraged us to try therapeutic CHPP for overt peritoneal dissemination.
 ...
PMID:[A case of disappearance of peritoneal dissemination in gastric cancer induced by continuous hyperthermic peritoneal perfusion with cisplatin and mitomycin C]. 313 3

A 47-year-old male was diagnosed as having gastric cancer with metastases to liver, para-aorta node and Virchow node. He was treated with EAP (Etoposide, Adriamycin, Cisplatin) therapy, as a result of which a partial response was obtained according to the criteria of the Jpn. Soc. Cancer. Ther. The response was disappearance of subjective symptoms and Virchow's metastasis and reduction of chief tumor and liver metastases. However, this therapy was accompanied by severe side effects such as leucopenia and thrombocytopenia, but in this case, these side effects improved within 20 days.
 ...
PMID:[A case of gastric carcinoma remarkably responding to etoposide, adriamycin and cisplatin (EAP) therapy]. 317 44

An in vitro chemosensitivity test, the succinate dehydrogenase inhibition (SDI) test, was used to examine 16 pairs of samples obtained simultaneously from primary and metastatic lesions of clinical gastric cancer. Concerning the metastases, 11 were in the lymph nodes and five in the liver. The chemosensitivities of metastatic lesions against six anti-tumour drugs, carboquone (CQ), adriamycin (ADM), mitomycin C (MMC), aclacinomycin A (ACR), and 5-fluorouracil (5-FU), differed from those in the primary lesions, and there were no correlations of chemosensitivities between the primary and the metastatic lesions against these drugs, except for DDP. The lymph nodes were more sensitive to CQ, ADM, MMC, DDP, ACR and 5-FU, while the liver was less sensitive than the primary lesions to CQ, ADM, MMC, DDP, and ACR. Our findings indicate that in patients with lymph node metastasis, there is a sensitivity to anti-tumour drugs, while in cases of liver metastasis, drug treatment may be less effective. We propose that chemosensitivity testing should be done when attempting to design anti-tumour drugs.
 ...
PMID:Chemosensitivity differences between primary and metastatic lesions of clinical gastric cancer. 319 5

In general, progress of chemotherapy for advanced gastrointestinal tumors has been slow, however, introduction of cisplatin has improved the results of chemotherapy in esophageal cancer. Cisplatin has been also recognized to be active for gastric cancer and study of combinations containing it is underway. Adriamycin appears to be the most active for hepatoma and 5-fluorouracil for pancreatic and colorectal cancers. Thus, combinations containing these drugs have been extensively studied but none has shown a definitive superiority over single agent efficacy of both drugs.
 ...
PMID:[Current status of chemotherapy of advanced gastrointestinal tumors]. 353 57

Sixteen evaluable patients with advanced gastric cancer who had no prior therapy were treated intravenously with cisplatin (DDP) 20 mg/m2/day on days 1-5 and with Adriamycin 40 mg/m2 and 5-fluorouracil 600 mg/m2 on day 1 (DAF) every 3 weeks. There were five objective partial responses, giving a response rate of 31%. Five patients had minor responses, and 5 others achieved disease stabilization. The median duration of response for responders was 10 months, and the median time to tumor progression in nonresponders was 6 months. The overall median survival was 12 months (responders 14 months, nonresponders 9 months; NS). Most patients had a subjective improvement, including disappearance of abdominal pain (7/9) and gastrointestinal bleeding (5/7). The drug toxicity was moderate to severe. The primary nonhematologic toxicities were nausea and vomiting (in all patients), severe weakness (44%), and parasthesias (31%). Eight patients (50%) experienced significant bone marrow suppression. The DAF combination appears to have some activity in patients with advanced gastric cancer. However, further efforts in new drug development and other combinations are needed to improve the results of chemotherapy in stomach cancer.
 ...
PMID:Treatment of advanced gastric cancer with DDP (cisplatin), adriamycin, and 5-fluorouracil (DAF). 361 11

A 51-year-old man with recurrent gastric cancer was treated by combined administration of Cisplatin and Carmofur. The target sites were the abdominal lymph nodes and the area of invasion to the stomach. Cisplatin (50 mg/body/day) was given for 3 days, while Carmofur (400-800 mg/body/day) was administered daily in 1 course. After 1 course of administration, the target tumor was reduced in size and the therapy was continued. A complete response was confirmed by upper gastrointestinal roentgenography, endoscopy and echography after 8 courses of Cisplatin administration. The patient has survived for 2 years 6 months in a state of CR. This case suggests that a combination therapy of Cisplatin and Fluoropyrimidine derivatives might be effective for gastric cancer.
 ...
PMID:[A case of recurrent gastric cancer successfully treated with a combination of cisplatin and carmofur]. 367 99

Cisplatin (CDDP) was administered by intravenous drip in 3 cases of gastrointestinal cancer, and by intraperitoneal spraying in 2 other similar cases; and free CDDP and total CDDP levels in blood were determined with time. In the former cases, the free CDDP level rose from 30 minutes after the start of intravenous drip, to reach a peak at 2 approximately 4 hours after the end of the drip, while it was undetectable at 24 hours. The total CDDP level reached a peak 4 hours after the start of the drip, and then gradually decreased at 24, 48, 72 and 96 hours, although it still remained detectable in blood. In the latter cases, free CDDP appeared in blood at 15 minutes after the spraying, and disappeared from blood in 30 minutes to 1 hour. The total CDDP level reached a peak at 30 minutes, and then decreased in a manner similar to that seen in cases given the intravenous drip. CDDP levels in resected stomachs, resected colon and dissected lymph nodes following intravenous drip of CDDP were then measured in 4 cases of stomach cancer and another of cancer of the descending colon. There was no significant difference in CDDP level between cancer tissues, non-cancer tissues and lymph nodes. It thus appears that CDDP is taken up equally by normal tissues and cancer tissues, and that it may be necessary to study the metabolic pathways of CDDP after it has been taken up by the tissues.
 ...
PMID:[A study of concentrations of CDDP in blood and cancer tissues in CDDP-treated gastrointestinal cancer]. 378 60

In a pilot study 16 patients with advanced inoperable stomach cancer were treated with Etoposide, Adriamycin, Cisplatin. The recommended dose for phase II studies was established and first therapy results are presented. Two of 16 patients responded with complete remissions and 8 with partial remissions. The recommended dose schedule for phase II studies is: Adriamycin 20 mg/m2 i.v. day 1 + 7; Cisplatin 40 mg/m2 i.v. day 2 + 8; Etoposide 120 mg/m2 i.v. day 4, 5, 6, every four weeks.
 ...
PMID:Advanced inoperable stomach cancer: a pilot study with the combination etoposide, adriamycin and cisplatin. 380 Mar 25

Information exchange with regard to new antitumor agents has taken place through meetings dealing with various treatment areas within the US-Japan Cancer Research Program, contact between the National Cancer Institute (NCI) in the USA and the Cancer Chemotherapy Center, and meetings of the Early Clinical Trial Group of the EORTC. Cisplatin. VP16-213, 6-Thioguanine, DTIC and AMSA which were judged to be worth introducing to Japan from information obtained from the above sources were supplied by the NCI and clinical trials have been conducted. A joint study of advanced gastric cancer was conducted between the Northern California Oncology Group and a Japanese Cooperative Group involving 13 major institutions through the US-Japan Program. The study was meaningful for understanding the natural history of patients with gastric cancer in both countries.
 ...
PMID:[Research project of cancer chemotherapy]. 392 Sep 68


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>